Results

Eli Lilly and Company

01/13/2020 | Press release | Distributed by Public on 01/13/2020 09:49

Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC